866-997-4948 (US-Canada Toll Free)

Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs

Published By :

GBI Research

Published Date : 2012-12-14

Category :

Pharmaceutical

No. of Pages : 78

Product Synopsis

Generic Growth Strategies Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs Summary GBI Research, the leading business intelligence provider, has released its latest research, Generic Growth Strategies Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs. The report provides a comprehensive overview of the generic drugs market in the US, the top five countries in the European Union (EU, covering the UK, France, Germany, Spain and Italy) and Japan. The report focuses on the detailed analysis of major strategies implemented by the top 10 generic companies in the generic drugs market along with company portfolios... Read More

Table Of Content

Table of Contents

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 10
1.2 List of Figures 10

2 Generic Growth Strategies - Introduction 11

3 Generic Growth Strategies - Market Overview 12
3.1 Overview of the Generics Market 12
3.1.1 Leading Generics Companies 12
3.1.2 Generics Market Share 14
3.2 Drivers and Restraints 15
3.2.1 Drivers 16
3.2.2 Restraints 21

4 Generic Growth Strategies - Regulatory Landscape 23
4.1 The US 23
4.1.1 Hatch-Waxman Act and ANDA 23
4.1.2 Shortening Market Exclusivity of Biopharmaceuticals and Impact on Generics 25
4.1.3 Pay-For-Delay Ban to be Detrimental to Innovators as Well as Generics 25
4.1.4 Cost-sharing of Generic Drugs 25
4.1.5 Impact of Supplemental Examination Provision of Patent Reform Act on Generics 26
4.1.6 Biologics Price Competition and Innovation Act Falls Short 26
4.2 Europe 28
4.2.1 Generic Penetration 28
4.2.2 Generic Substitution 29
4.2.3 Pricing and Reimbursement 29
4.2.4 Marketing Authorization for Generics 29
4.2.5 Generic Landscape in Leading European Markets 29
4.2.6 Common European Union Patent System 31
4.2.7 Tendering 32
4.2.8 Regulatory Landscape for Biosimilars 32
4.2.9 The Future of Biosimilars is Advancing Along a Path Smoothened by European Groundwork 32
4.3 Japan 33
4.3.1 Generics 33
4.3.2 Biosimilar 34

5 Generic Growth Strategies - Major Strategies 35
5.1 Authorized Generics 35
5.1.1 Case Study 37
5.2 Mergers and Acquisitions 37
5.2.1 Vertical Integration 39
5.2.2 Therapeutic Expansion - Biosimilars 39
5.3 Outsourcing 40
5.3.1 Outsourcing Opportunities in Biosimilars 40
5.3.2 Outsourcing is Also a Source of Income for Generics Companies 40
5.4 Marketing Partnership 41
5.4.1 Case Studies 41
5.5 Paragraph IV Certifications 42
5.5.1 Case Studies 42
5.5.2 Example of a Paragraph IV Challenge That Did Not Work Out for a Generic 42
5.6 R&D Strategies Employed by Key Players in the Generics Market 43
5.6.1 Super Generics 43
5.6.2 Biosimilars 44
5.7 Increasing Awareness and Acceptance 46

6 Generic Growth Strategies - Competitive Landscape 47
6.1 Teva Pharmaceutical Industries Limited 47
6.1.1 Overview 47
6.1.2 Revenue Analysis 47
6.1.3 Therapeutic Focus 48
6.1.4 Geographic Focus 48
6.1.5 Generic Growth Strategies 48
6.1.6 SWOT 51
6.2 Sandoz 52
6.2.1 Overview 52
6.2.2 Revenue Analysis 52
6.2.3 Therapeutic Focus 52
6.2.4 Geographic Focus 52
6.2.5 Generic Growth Strategies 53
6.2.6 SWOT 54
6.3 Mylan 55
6.3.1 Overview 55
6.3.2 Revenue Analysis 55
6.3.3 Therapeutic Focus 55
6.3.4 Geographic Focus 55
6.3.5 Generic Growth Strategies 57
6.3.6 SWOT 58
6.4 Watson 59
6.4.1 Overview 59
6.4.2 Revenue Analysis 59
6.4.3 Therapeutic Focus 59
6.4.4 Geographic Focus 59
6.4.5 Generic Growth Strategies 60
6.4.6 SWOT 61
6.5 Actavis 62
6.5.1 Overview 62
6.5.2 Revenue Analysis 62
6.5.3 Therapeutic Focus 62
6.5.4 Geographic Focus 62
6.5.5 Generic Growth Strategies 62
6.5.6 SWOT 63
6.6 Hospira 64
6.6.1 Overview 64
6.6.2 Revenue Analysis 64
6.6.3 Therapeutic Focus 64
6.6.4 Geographic Focus 64
6.6.5 Generic Growth Strategies 65
6.6.6 SWOT 66
6.7 Sanofi 67
6.7.1 Overview 67
6.7.2 Revenue Analysis 67
6.7.3 Geographic Focus 67
6.7.4 Generic Growth Strategies 67
6.7.5 SWOT 68
6.8 Daiichi Sankyo 68
6.8.1 Overview 68
6.8.2 Revenue Analysis 68
6.8.3 Geographic Focus 68
6.8.4 Generic Growth Strategies 68
6.8.5 SWOT 69
6.9 Aspen 69
6.9.1 Overview 69
6.9.2 Revenue Analysis 69
6.9.3 Geographic Focus 69
6.9.4 Generic Growth Strategies 70
6.9.5 SWOT 70
6.10 STADA 71
6.10.1 Overview 71
6.10.2 Revenue Analysis 71
6.10.3 Therapeutic Focus 71
6.10.4 Geographic Focus 71
6.10.5 Generic Growth Strategies 72
6.10.6 SWOT 72

7 Generic Growth Strategies - Conclusion 73

8 Generic Growth Strategies - Appendix 74
8.1 Market Definitions 74
8.2 Abbreviations 74
8.3 Bibliography 75
8.4 Research Methodology 77
8.4.1 Coverage 77
8.4.2 Secondary Research 77
8.4.3 Primary Research 78
8.4.4 Expert Panel Validation 78
8.5 Contact Us 78
8.6 Disclaimer 78

List of Tables


Table 1: Generic Growth Strategies, Global, Revenues of Leading Generic Companies ($bn), 2010-2011 13
Table 2: Generic Growth Strategies, Global, Revenues of Major Drugs Due for Patent Expiry ($m), 2013-2020 17
Table 3: Generic Growth Strategies, Number of Generic ANDA Filed and Approvals, 2006-2011 18
Table 4: Generic Growth Strategies, ANDA Approvals by Month, The US, 2011-2012 19
Table 5: Generic Growth Strategies, Number of EMA Authorized Generics, Europe, 2007-2012 20
Table 6: Generic Growth Strategies, Number of Biosimilars Authorized by the EMA, Europe, 2006-2012 22
Table 7: Generic Growth Strategies, The US, Generic Drug Cost-Sharing (%), 2011-2020 26
Table 8: Generic Growth Strategies, Notable Authorized Generics Entry, The US, 2010-2012 35
Table 9: Generic Growth Strategies, Generic Products Launched, Teva, The US, 2011 49
Table 10: Generic Growth Strategies, Top Five Generic Active Ingredients, STADA Group, Revenue ($m), 2011 71

List of Figures


Figure 1: Generic Growth Strategies, Global, Revenues of Leading Generic Companies ($bn), 2010-2011 13
Figure 2: Generic Growth Strategies, Generic Market Share in Selected Countries, 2010 14
Figure 3: Generic Growth Strategies, Drivers and Restraints, 2012 15
Figure 4: Generic Growth Strategies, Global, Revenues of Top 10 Drugs Due for Patent Expiry ($m), 2013-2020 16
Figure 5: Generic Growth Strategies, Number of Generic ANDA Filed and Approvals, 2006-2011 18
Figure 6: Generic Growth Strategies, ANDA Approvals by Month, The US, 2011-2012 19
Figure 7: Generic Growth Strategies, Number of EMA Authorized Generics, Europe, 2007-2012 20
Figure 8: Generic Growth Strategies, Number of Biosimilars Authorized by the EMA, Europe, 2006-2012 22
Figure 9: Generic Growth Strategies, The US, Generic Drug Cost-Sharing (%), 2011-2020 25
Figure 10: Generic Growth Strategies, SWOT Analysis, Teva, 2012 51
Figure 11: Generic Growth Strategies, SWOT Analysis, Sandoz, 2012 54
Figure 12: Generic Growth Strategies, SWOT Analysis, Mylan, 2012 58
Figure 13: Generic Growth Strategies, SWOT Analysis, Watson, 2012 61
Figure 14: Generic Growth Strategies, SWOT Analysis, Actavis, 2012 63
Figure 15: Generic Growth Strategies, SWOT Analysis, Hospira, 2012 66
Figure 16: Generic Growth Strategies, SWOT Analysis, Sanofi, 2012 68
Figure 17: Generic Growth Strategies, SWOT Analysis, Daiichi Sankyo, 2012 69
Figure 18: Generic Growth Strategies, SWOT Analysis, Aspen, 2012 70
Figure 19: Generic Growth Strategies, SWOT Analysis, STADA Arzneimittel AG, 2012 72

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Specialty Enzymes Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    By - Transparency

    Specialty enzymes are used to increase protein content in plants and animals. Specialty enzymes are natural proteins produced by living organisms and are majorly used in production of pharmaceuticals products, biocatalysts and research & development and diagnostics solutions.  Every activity of the body such as conversion of food to energy, disposal of waste materials, replacement of old tissue, building new tissues, and reproduction requires enzymes. The market for specialty enzymes can be segmented on the basis of product type such as proteases, carbohydrases,...

  • Industrial And Specialty Gases Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018

    By - Transparency

    Gases which are sold for general purpose to industries, mainly based on air gases and other related gases are known as industrial gases. Gases which are critical components for industries such as chemicals, materials processing, foods, semiconductors, medical, biotechnology, and environmental are known as specialty gases. The global market for industrial and specialty gases is expected to reach 10.15 trillion cubic feet by 2015.In 2009, the market for industrial and specialty gas experienced a fall due to worldwide economic slowdown. The U.S. is the market leader followed by...

  • Methanol Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018

    By - Transparency

    Methanol is the liquefied form of methane, a gas which is usually produced as a result of the decomposition of organic matter. Methanol is one of the better alternatives available for contemporary gasoline products as it dispenses the same amount of energy. It also acts as an additive in petroleum products, boosting the performance of internal combustion engines. Methanol is also called methyl alcohol or wood alcohol and is naturally found in volcanic gases and wood. Some of the major factors driving the global methanol market include efficiency of plants in producing the gas,...